Orexin drugs spark a new multibillion-dollar race to control wakefulness

A new class of orexin agonists is being positioned as the neuroscience equivalent of GLP-1 drugs. Orexins are brain peptides that regulate wakefulness, and the drugs aim to restore that signaling rather than merely stimulate the nervous system.

Takeda’s oveporexton received U.S. approval in August 2026 under the brand name Orzeyful for adults with narcolepsy type 1. It is described as the first approved medicine targeting the underlying orexin deficiency in that disease.

The commercial race is intensifying. Eli Lilly agreed to acquire Centessa Pharmaceuticals for about $6.3 billion upfront, potentially reaching $7.8 billion, to obtain its orexin program, including ORX750.

Other companies, including Alkermes, are advancing competing OX2R agonists. Clinical development is expanding beyond narcolepsy type 1 into narcolepsy type 2 and idiopathic hypersomnia.

Analysts estimate that orexin medicines could produce roughly $15–20 billion annually by the mid-2030s in narcolepsy and related sleep disorders alone. The opportunity could be larger if trials support uses in fatigue, attention, cognition, mood, or other neurological conditions.

The key scientific promise is more physiological, sustained wakefulness with fewer drawbacks than traditional stimulants. However, broader applications remain speculative, and safety, long-term effects, abuse potential, and the difficulty of treating people who are merely tired rather than orexin-deficient remain important uncertainties.